Teriparatide injection

Drug Profile

Teriparatide injection

Alternative Names: Forsteo; Forteo; hPTH 1-34; LY 333334; MN 10T; Parathar; Parathyroid hormone (1-34); PTH; Teriparatide; Teriparatide acetate

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Eli Lilly
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Male osteoporosis; Osteoporosis; Postmenopausal osteoporosis
  • Phase III Fracture
  • Market Withdrawal Hypoparathyroidism

Most Recent Events

  • 16 Sep 2016 Pharmacodynamics data from the EUROFORS study presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2016)
  • 17 Jun 2015 EudraCT2006-004110-40 - Added trial info
  • 06 Jan 2014 Eli Lilly completes an international phase III trial in Fracture treatment (NCT01473589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top